moneyheap
ENOV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Enovis Corporation (ENOV) stock moving?
Enovis reported Q3 2026 results on Nov 5 with adjusted EPS of $0.88 versus a $0.77 estimate and sales of $558.7M, a slight beat. It raised FY2026 adjusted EPS guidance to $3.58-$3.79, which is above the $3.63 consensus, and narrowed sales guidance to $2.320B-$2.350B, whose midpoint of $2.335B sits marginally below the $2.339B estimate. A new $200M buyback was announced. Analysts responded with a cluster of notes: BTIG raised its target to $42, Needham to $38, Wells Fargo to $37 and Evercore to $33, while Canaccord kept a Buy rating and trimmed its target to $42 from $45. The price action confirms the reaction: shares rose 12% on Nov 4 to $24.42 on 3.8M shares, then gapped up on Nov 5 to a $28.43 open with a $29.89 high and a $28.62 close on 5.6M shares, roughly four times the 30-day norm. Since then the stock has held between $28.0 and $28.5, closing at $28.22 on Nov 10, so the gap has largely held. Earlier, shares fell 13% on Oct 30 to $19.91 on heavy volume, and no news item in the set explains that drop. The 10-Q filed Nov 5 was provided without content, so balance-sheet and segment detail is not reflected here. The main risks are a post-gap pullback and the narrowed sales outlook.
News behind the analysis
- Enovis Reports Third Quarter 2026 Financial Results and Announces New Share Repurchase AuthorizationEnovis reported Q3 2026 results that exceeded analyst expectations for adjusted EPS and announced a new $200 million share repurchase program.
- Enovis Q3 Adj. EPS $0.88 Beats $0.77 Estimate, Sales $558.725M Beat $557.010M EstimateThird-quarter adjusted EPS of $0.88 beat the $0.77 estimate, and sales of $558.7M edged past the $557.0M estimate.
- Enovis Raises FY2026 Adj EPS Guidance from $3.52-$3.73 to $3.58-$3.79 vs $3.63 Est; Narrows FY2026 Sales Guidance from $2.310B-$2.370B to $2.320B-$2.350B vs $2.339B EstFull-year adjusted EPS guidance was raised to $3.58-$3.79, while sales guidance was narrowed to $2.320B-$2.350B, with the midpoint slightly below the $2.339B estimate.
- BTIG Maintains Buy Rating on Enovis and Raises Price TargetBTIG kept its Buy rating and raised its price target from $36 to $42 after the quarter.
- Needham Maintains Buy Rating and Raises Price Target for EnovisFollowing the Q3 report, Needham maintained its Buy rating and raised its price target from $34 to $38.
- Evercore ISI Group Maintains Outperform on Enovis, Raises Price Target to $33Evercore ISI Group kept its Outperform rating and raised its price target to $33.
- Wells Fargo Maintains Overweight on Enovis, Raises Price Target to $37Wells Fargo kept its Overweight rating and raised its price target to $37.
- Canaccord Genuity Maintains Buy Rating on Enovis, Adjusts Price TargetCanaccord Genuity reaffirmed its Buy rating but lowered its price target from $45 to $42.
- Enovis Expands Implant Compatibility for HipInsight SystemEnovis expanded the range of compatible femoral and acetabular systems for its HipInsight open-platform surgical technology.
About Enovis Corporation
Enovis is a Dallas-based medical technology company that makes orthopedic products, from artificial joint implants to braces and rehab equipment. It was created from the former Colfax Corporation, which spun off its welding business, ESAB, in 2022. Enovis then grew its implant business by buying Italy's LimaCorporate, and it has made a binding offer to buy eCential Robotics, a surgical robotics company.
How it makes money
Enovis sells products in two segments. Reconstructive accounts for slightly over half of sales and covers hip, knee, shoulder and extremity implants plus related surgical tools. Prevention & Recovery, slightly under half, includes bracing, supports and rehab products under brands like DJO and Chattanooga. The company expects 2026 revenue of about $2.3 billion, and its products are sold mainly to hospitals, surgeons, clinics and physical therapists.
What usually moves ENOV
- Number of joint replacement surgeries and how many patients are having procedures
- How fast the Reconstructive implant business grows and new product launches
- Margin improvement and the integration of acquisitions such as LimaCorporate and eCential Robotics
- Debt levels and free cash flow
- Hospital reimbursement rates, pricing pressure and foreign currency swings